Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1073-1078

  Wild, Damian ^a,b   Christ, Emanuel ^c   Caplin, Martyn E ^d   Kurzawinski, Tom R ^a   Forrer, Flavio ^e   Brändle, Michael ^f   Seufert, Jochen ^b   Weber, Wolfgang A ^b   Bomanji, Jamshed ^a   Perren, Aurel ^g   Ell, Peter J ^a   Reubi, Jean Claude ^g  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f Kantonsspital St Gallen ^*  (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Glucagon like peptide 1 receptor targeting; Insulinoma; Peptide receptor radionuclide therapy; Somatostatin receptor subtype 2 targeting

Indexed keywords

DIAZOXIDE; DOTATATE GA 68; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG TARGETING; FEMALE; HUMAN; IN VITRO STUDY; INSULINOMA; MALE; MALIGNANT INSULINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERINSULINISM; HYPOGLYCEMIA; INSULINOMA; MALE; MIDDLE AGED; RECEPTORS, GLUCAGON; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960296365     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.085142     Document Type: Article

References (20)

1. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783-798.
2. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma: incidence, recurrence, and long-term survival of patients - a 60-year study. Mayo Clin Proc. 1991;66:711-719.
3. Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222-3226.
4. Lepage C, Ciccolallo L, De Angelis R, et al. European disparities in malignant digestive endocrine tumours survival. J Cancer. 2010;126:2928-2934.
5. Grama D, Eriksson B, Martensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg. 1992;16:632-639.
6. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16.
7. Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327-331.
8. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793. (Pubitemid 36612963)
9. Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept. 2006;137:162-167. (Pubitemid 44838980)
10. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-2033.
11. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
12. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
13. Wild D, Theodoraki A, Kurzawinski TR, et al. 'Running on empty'. Eur J Nucl Med Mol Imaging. 2010;37:1439-1440.
14. 2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res. 2007;13:3696-3705.
15. 3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
16. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-945.
17. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743. (Pubitemid 47604973)
18. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846. (Pubitemid 32662546)
19. 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31:1025-1032.
20. Zimmer T, Stolzel U, Bader M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996;39:562-568. (Pubitemid 26376040)